Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company was directed to submit a plan of compliance by July 15, 2022
MedTel aims to raise series A for rapid business expansion, product improvement & conducting relevant clinical validation studies.
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The 41,000 sq ft facility will be utilized to manufacture clinical to commercial-grade peptide products for increased manufacturing capacity
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
Subscribe To Our Newsletter & Stay Updated